NANOLEK and scientific-production company KOMBIOTEKH announced the partnership on domestic production 4-valent vaccine against human papillomavirus (HPV) 4 types (6, 11, 16, 18). Investment in the project will amount to about 1.8 billion rubles.
The vaccine will be produced in full cycle production capacities NANOLEK in the Kirov region in full compliance with GMP standards and technical requirements for the production of such vaccines. The vaccine has a high export potential, noted by the parties. To date, the who increased purchases and predicts supply shortages of the vaccine in the future, so the project also involves an export component (planned prequalification of the vaccine according to the who requirements). Until 2027, the who predicts a shortage of the vaccine in up to one third of the demand.
According to the world health organization, cervical cancer is the only cancer that is preventable by primary prevention with HPV vaccination. In Russia, the economic damage from cervical cancer associated with HPV is 50 billion rubles. per year.